Related Experiment Video
Updated: Dec 11, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
Carin A Uyl-de Groot1, Renaud Heine1, Marieke Krol2
1Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burg Oudlaan 50, 3062 PA Rotterdam, The Netherlands.
Background:
Many new cancer medicines have been developed that can improve patients' outcomes. However, access to these agents comes later in Europe than in the United States (US). The aim of this study is to assess the access in Europe to newly registered cancer drugs and to get more insight in the implications of these variations for patients.
Methods:
A retrospective database study was conducted. Analyses involved 12 cancer drugs and 28 European countries in the period 2011-2018. Time to patient access, speed of drug uptake, and the potential loss of life years due to a delay in access have been studied.
Results:
Marketing approval for the cancer drugs came on average 242 days later in Europe than in the US, and actual patient access varied extensively across Europe. The average time to market in Europe was 403 days (range 17-1187 days). The delay in patient access of ipilimumab and abiraterone may have led to a potential loss of more than 30,000 life years.
Conclusion:
It takes a long time for patients to get access to newly registered cancer drugs and there is great variation in access. The health outcomes can be substantially improved by faster processes.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:49Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
Published on: June 16, 2022
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Drug Products: Biologics, Biosimilars and Interchangeables
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer
Drug Regulation